Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure

References

• Hunt PJ, Richards AM, Nicholls MG et al. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT-PROBNP), a new marker of cardiac impairment. Clin. Endocrinol. (Oxf.)47(3), 287–296 (1997).
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med.325(5), 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am. J. Cardiol.78(8), 902–907 (1996).
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II), a randomised trial. Lancet353(9146), 9–13 (1999).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med.327(10), 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• Jamieson JD, Palade GE. Specific granules in atrial muscle cells. J. Cell Biol.23, 151–172 (1964).
   PubMed Web of Science ®Google Scholar
• Kisch B. Electronmicroscopy of the atrium of the heart. Exp. Med. Surg.14(2–3), 99–112 (1956).
   PubMedGoogle Scholar
• Kisch B. A significant electron microscopic difference between the atria and ventricles of the mammalian heart. Exp. Med. Surg.21, 193–221 (1963).
   PubMedGoogle Scholar
• de Bold AB, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Science28, 89–94 (1981).
   PubMed Web of Science ®Google Scholar
• Sudoh T, Kangawa K, Minamino N et al. A new natriuretic peptide in porcine brain. Nature332(6159), 78–81 (1988).
   PubMed Web of Science ®Google Scholar
• Maeda K, Tsutamoto T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart J.135(5 Pt 1), 825–832 (1998).
   PubMed Web of Science ®Google Scholar
• Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation96(2), 509–516 (1997).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med.347(3), 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• McCullough PA, Nowak RM, McCord J et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation106(4), 416–422 (2002).
   PubMed Web of Science ®Google Scholar
• Dao Q, Krishnaswamy, Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol.37(2), 379–385 (2001).
   PubMed Web of Science ®Google Scholar
• Hystad ME, Geiran OR, Attramadal H et al. Regional cardiac expression and concentration of natriuretic peptides in patients with severe chronic heart failure. Acta. Physiol. Scand.171(4), 395–403 (2001).
   PubMedGoogle Scholar
• Luchner A, Stevens TL, Borgeson DD et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am. J. Physiol.274(5 Pt 2), H1684–H1689 (1998).
   PubMed Web of Science ®Google Scholar
• Cheng V, Garcia A, Kazanagra R et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J. Am. Cardiol.37, 386–391 (2001).
   Web of Science ®Google Scholar
• Magga J, Marttila M, Mantymaa P et al. Brain natriuretic peptide in plasma, atria, and ventricles of vasopressin- and phenylephrine-infused conscious rats. Endocrinology134(6), 2505–2515 (1994).
   Google Scholar
• Magga J, Vuolteenaho O, Tokola H et al. B-type natriuretic peptide: a myocyte-specific marker for characterizing load-induced alterations in cardiac gene expression. Ann. Med.30(Suppl 1), 39–45 (1998).
   Google Scholar
• Richards AM,Crozier IG, Yandle TG, Espiner EA, Ikram H, Nicholls MG. Brain natriuretic factor: regional plasma concentrations and correlation with hemodynamic state in cardiac disease. Br. Heart J.69, 414–417 (1993).
   PubMedGoogle Scholar
• Richards AM, McDonald D, Fitzpatrick MA et al. Atrial natriuretic hormone has biological effects in man at physiological plasma concentrations. J. Clin. Endocrinol. Metab.67(6), 1134–1139 (1988).
   PubMed Web of Science ®Google Scholar
• Valli N, Gobinet A, Bordenave L. Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J. Lab. Clin. Med.134(5), 437–444 (1999).
   PubMed Web of Science ®Google Scholar
• McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev. Cardiovasc. Med.4(2), 72–80 (2003).
   PubMedGoogle Scholar
• Karabulut A, Kaplan A, Aslan C et al. The association between NT-proBNP levels, functional capacity and stage in patients with heart failure. Acta Cardiol.60(6), 631–638 (2005).
   PubMed Web of Science ®Google Scholar
• Koglin J, Pehlivanli S, Schwaiblmair M et al. Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J. Am. Coll. Cardiol.38(7), 1934–1941 (2001).
   PubMed Web of Science ®Google Scholar
• Lee SC, Stevens TL, Sandberg SM et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J. Card. Fail.8(3), 149–154 (2002).
   PubMed Web of Science ®Google Scholar
• Yeo KT, Wu AH, Apple FS et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin. Chim. Acta338(1–2), 107–115 (2003).
   PubMed Web of Science ®Google Scholar
• Belenky A, Smith A, Zhang B et al. The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin. Chim. Acta340(1–2), 163–172 (2004).
   PubMed Web of Science ®Google Scholar
• Shimizu H, Aono K, Masuta K et al. Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin. Chim. Acta305(1–2), 181–186 (2001).
   PubMed Web of Science ®Google Scholar
• Hawkridge AM, Heublein DM, Bergen HR 3rd et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl Acad. Sci. USA102(48), 17442–17447 (2005).
   PubMed Web of Science ®Google Scholar
• McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet351(9095), 9–13 (1998).
   PubMed Web of Science ®Google Scholar
• Bay M, Kirk V, Parner J et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart89(2), 150–154 (2003).
   PubMed Web of Science ®Google Scholar
• O’Donoghue M, Chen A, Baggish AL et al. The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J. Card. Fail.11(Suppl. 5), S9–S14 (2005).
   PubMed Web of Science ®Google Scholar
• Groenning BA, Nilsson JC, Sondergaard L et al. Detection of left ventricular enlargement and impaired systolic function with plasma N-terminal pro brain natriuretic peptide concentrations. Am. Heart J.143(5), 923–929 (2002).
   PubMed Web of Science ®Google Scholar
• Valle R, Aspromonte N, Barro S et al. The NT-proBNP assay identifies very elderly nursing home residents suffering from pre-clinical heart failure. Eur. J. Heart Fail.7(4), 542–551 (2005).
   PubMed Web of Science ®Google Scholar
• Galasko GI, Lahiri A, Barnes SC et al. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur. Heart J.26(21), 2269–2276 (2005).
   PubMed Web of Science ®Google Scholar
• Talwar S, Squire IB, Davies JE et al. Plasma N-terminal pro-brain natriuretic peptide and the ECG in the assessment of left-ventricular systolic dysfunction in a high risk population. Eur. Heart J.20(23), 1736–1744 (1999).
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Davis RC, Roalfe AK et al. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br. Med. J.324(7352), 1498 (2002).
   PubMed Web of Science ®Google Scholar
• Groenning BA, Raymond I, Hildebrandt PR et al. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart90(3), 297–303 (2002).
   Web of Science ®Google Scholar
• McDonagh TA, Holmer S, Raymond I et al. NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur. J. Heart Fail.6(3), 269–273 (2004).
   PubMed Web of Science ®Google Scholar
• Cabanes L, Richaud-Thiriez B, Fulla Y et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest120(6), 2047–2050 (2001).
   PubMed Web of Science ®Google Scholar
• Davis M, Espiner E, Richards G et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet343(8895), 440–444 (1994).
   PubMed Web of Science ®Google Scholar
• Morrison LK, Harrison A, Krishnaswamy P et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol.39(2), 202–209 (2002).
   PubMed Web of Science ®Google Scholar
• Lainchbury JG, Campbell E, Frampton CM et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J. Am. Coll. Cardiol.42(4), 728–735 (2003).
   PubMed Web of Science ®Google Scholar
• Bayes-Genis A, Bellido-Casado J, Zapico E et al. N-terminal pro-brain natriuretic peptide reflects pulmonary capillary leakage in patients with acute dyspnea. Am. J. Cardiol.94(5), 669–670 (2004).
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Camargo CA, Anwaruddin S et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am. J. Cardiol.95(8), 948–954 (2005).
   PubMed Web of Science ®Google Scholar
• Baggish AL, Siebert U, Lainchbury JG et al. A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. Am. Heart J.151(1), 48–54 (2006).
   PubMed Web of Science ®Google Scholar
• Baggish A, Cameron R, Anwaruddin S et al. A clinical and biochemical critical pathway for the evaluation of patients with suspected acute congestive heart failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) algorithm. Crit. Pathways Cardiol.3, 171–176 (2004).
   PubMedGoogle Scholar
• Chen AA, Wood MJ, Krauser DG et al. NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. Eur. Heart J.27(7), 839–845 (2006).
   PubMed Web of Science ®Google Scholar
• Januzzi JL, van Kimmenade R, Lainchbury J et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur. Heart J.27(3), 330–337 (2006).
   PubMed Web of Science ®Google Scholar
• Dauterman KW, Massie BM, Gheorghiade M. Heart failure associated with preserved systolic function: a common and costly clinical entity. Am. Heart J.135(6 Pt 2 Su), S310–S319 (1998).
   PubMed Web of Science ®Google Scholar
• Senni M, Tribouilloy CM, Rodeheffer RJ et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County Minnesota. Circulation98(21), 2282–2289 (1991).
   Google Scholar
• Vasan RS, Larson MG, Benjamin EJ et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J. Am. Coll. Cardiol.33(7), 1948–1955 (1999).
   PubMed Web of Science ®Google Scholar
• Hammerer-Lercher A, Ludwig W, Falkensammer G et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin. Chem.50(7), 1174–1183 (2004).
   PubMed Web of Science ®Google Scholar
• Maisel AS, McCord J, Nowak RM et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J. Am. Coll. Cardiol.41(11), 2010–2017 (2003).
   PubMed Web of Science ®Google Scholar
• Richards AM, Doughty R, Nicholls MG et al. Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia–New Zealand Heart Failure Group. Circulation99(6), 786–792 (1999).
   PubMed Web of Science ®Google Scholar
• Richards AM, Doughty R, Nicholls MG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia–New Zealand Heart Failure Group. J. Am. Coll. Cardiol.37(7), 1781–1787 (2001).
   PubMed Web of Science ®Google Scholar
• Hartmann F, Packer M, Coats AJ et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation110(13), 1780–1786 (2004).
   PubMed Web of Science ®Google Scholar
• Gardner RS, Ozalp F, Murday AJ et al. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur. Heart J.24(19), 1735–1743 (2003).
   PubMed Web of Science ®Google Scholar
• Kirk V, Bay M, Parner J et al. N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur. J. Heart Fail.6(3), 335–341 (2004).
   PubMed Web of Science ®Google Scholar
• Bettencourt Ferreira S, Azevedo A et al. Preliminary data on the potential usefulness of B-type natriuretic peptide levels in predicting outcome after hospital discharge in patients with heart failure. Am. J. Med.113(3), 215–219 (2002).
   PubMed Web of Science ®Google Scholar
• O’Brien RJ, Squire IB, Demme B et al. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur. J. Heart Fail.5(4), 499–506 (2003).
   PubMed Web of Science ®Google Scholar
• Januzzi JL Jr, Sakhuja R, O’Donoghue M et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch. Intern. Med.166(3), 315–320 (2006).
   PubMedGoogle Scholar
• Gardner RS, Chong V, Morton I et al. N-terminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur. J. Heart Fail.7(2), 253–260 (2005).
   PubMed Web of Science ®Google Scholar
• Rothenburger M, Wichter T, Schmid C et al. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. J. Heart Lung Transplant.23(10), 1189–1197 (2004).
   PubMed Web of Science ®Google Scholar
• Cuppoletti A, Roig E, Perez-Villa F et al. Value of NT-proBNP determinations in the follow-up of heart transplantation. Transplant Proc.37(9), 4033–4035 (2005).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Frampton CM, Yandle TG et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet355(9210), 1126–1130 (2000).
   PubMed Web of Science ®Google Scholar
• Bettencourt, Azevedo A, Pimenta J et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation110(15), 2168–2174 (2004).
   PubMed Web of Science ®Google Scholar
• Fitzgerald RL, Cremo R, Gardetto N et al. Effect of nesiritide in combination with standard therapy on serum concentrations of natriuretic peptides in patients admitted for decompensated congestive heart failure. Am. Heart J.150(3), 471–477 (2005).
   PubMed Web of Science ®Google Scholar
• Miller WL, Hartman KA, Burritt MF et al. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin. Chem.51(3), 569–577 (2005).
   PubMed Web of Science ®Google Scholar
• Raymond I, Groenning BA, Hildebrandt PR et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart89(7), 745–751 (2003).
   PubMed Web of Science ®Google Scholar
• Redfield MM, Rodeheffer RJ, Jacobsen SJ et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol.40(5), 976–982 (2002).
   PubMed Web of Science ®Google Scholar
• Hogenhuis J, Voors AA, Jaarsma T et al. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur. J. Heart Fail.7(1), 81–86 (2005).
   PubMed Web of Science ®Google Scholar
• Schou M, Dalsgaard MK, Clemmesen O et al. Kidneys extract BNP and NT-proBNP in healthy young men. J. Appl. Physiol.99(5), 1676–1680 (2005).
   Google Scholar
• Chenevier-Gobeaux C, Claessens YE, Voyer S et al. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the emergency department: comparison with brain natriuretic peptide (BNP). Clin. Chim. Acta361(1–2), 167–175 (2005).
   PubMed Web of Science ®Google Scholar
• Anwaruddin S, Lloyd-Jones DM, Baggish A et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J. Am. Coll. Cardiol.47(1), 91–97 (2006).
   PubMed Web of Science ®Google Scholar
• Krauser DG, Lloyd-Jones DM, Chae CU et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am. Heart J.149(4), 744–750 (2005).
   PubMed Web of Science ®Google Scholar
• James SK, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation108(3), 275–281 (2003).
   PubMed Web of Science ®Google Scholar
• Jarai R, Iordanova N, Raffetseder A et al. Risk assessment in patients with unstable angina/non-ST-elevation myocardial infarction and normal N-terminal pro-brain natriuretic peptide levels by N-terminal pro-atrial natriuretic peptide. Eur. Heart J.26(3), 250–256 (2005).
   PubMedGoogle Scholar
• Jernberg T, Lindahl B, Siegbahn A et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J. Am. Coll. Cardiol.42(11), 1909–1916 (2003).
   PubMed Web of Science ®Google Scholar
• Jernberg T, Stridsberg M, Venge P et al. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J. Am. Coll. Cardiol.40(3), 437–445 (2002).
   PubMed Web of Science ®Google Scholar
• Omland T, Aakvaag A, Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation93(11), 1963–1969 (1996).
   PubMed Web of Science ®Google Scholar
• Schnabel R, Rupprecht HJ, Lackner KJ et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur. Heart J.26(3), 241–249 (2005).
   PubMed Web of Science ®Google Scholar
• Richards AM, Nicholls MG, Yandle TG et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation97(19), 1921–1929 (1998).
   PubMed Web of Science ®Google Scholar
• Lindahl B, Lindback J, Jernberg T et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J. Am. Coll. Cardiol.45(4), 533–541 (2005).
   PubMed Web of Science ®Google Scholar
• Hong SN, Yoon NS, Ahn Y et al. N-terminal pro-B-type natriuretic Peptide predicts significant coronary artery lesion in the unstable angina patients with normal electrocardiogram, echocardiogram, and cardiac enzymes. Circ. J.69(12), 1472–1476 (2005).
   PubMed Web of Science ®Google Scholar
• Weber M, Arnold R, Rau M et al. Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am. J. Cardiol.94(6), 740–745 (2004).
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N. Engl. J. Med.352(7), 666–675 (2005).
   PubMed Web of Science ®Google Scholar
• Kucher N, Printzen G, Doernhoefer T et al. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation107(12), 1576–1578 (2003).
   PubMed Web of Science ®Google Scholar
• Pruszczyk Kostrubiec M, Bochowicz A et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur. Respir. J.22(4), 649–653 (2003).
   PubMed Web of Science ®Google Scholar
• Gerber IL, Legget ME, West TM et al. Usefulness of serial measurement of N-terminal pro-brain natriuretic peptide plasma levels in asymptomatic patients with aortic stenosis to predict symptomatic deterioration. Am. J. Cardiol.95(7), 898–901 (2005).
   PubMed Web of Science ®Google Scholar
• Gerber IL, Stewart RA, Legget ME et al. Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation107(14), 1884–1890 (2003).
   PubMed Web of Science ®Google Scholar
• Kupari M, Turto H, Lommi J et al. Transcardiac gradients of N-terminal B-type natriuretic peptide in aortic valve stenosis. Eur. J. Heart Fail.7(5), 809–814 (2005).
   PubMed Web of Science ®Google Scholar
• Weber M, Arnold R, Rau M et al. Relation of N-terminal pro B-type natriuretic peptide to progression of aortic valve disease. Eur. Heart J.26(10), 1023–1030 (2005).
   PubMed Web of Science ®Google Scholar
• Sutton TM, Stewart RA, Gerber IL et al. Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J. Am. Coll. Cardiol.41(12), 2280–2287 (2003).
   PubMed Web of Science ®Google Scholar
• Arat-Ozkan A, Kaya A, Yigit Z et al. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with mitral stenosis. Echocardiography22(6), 473–478 (2005).
   PubMed Web of Science ®Google Scholar
• Beer S, Golay S, Bardy D et al. Increased plasma levels of N-terminal brain natriuretic peptide (NT-proBNP) in Type 2 diabetic patients with vascular complications. Diabetes Metab.31(6), 567–573 (2005).
   PubMed Web of Science ®Google Scholar
• Gaede, Hildebrandt, Hess G et al. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia48(1), 156–163 (2005).
   PubMed Web of Science ®Google Scholar
• Tarnow L, Hildebrandt, Hansen BV et al. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia48(1), 149–155 (2005).
   PubMed Web of Science ®Google Scholar
• McCullough PA, Duc P, Omland T et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am. J. Kidney Dis.41(3), 571–579 (2003).
   PubMed Web of Science ®Google Scholar